Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Critically-ill COVID-19
NCT04441424Completed
- Sponsor
- Al-Karkh Health Directorate
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Al-Karkh Health Directorate. Primary endpoint: Death versus survival of treated patients at 8 weeks. Started Apr 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04441424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441424.